Form 4: Cardinal Health Executive Jessica L. Mayer Reports Stock Transactions

Sentiment:

SEC Filing


Jessica L. Mayer, Chief Legal/Compliance Officer of Cardinal Health, reports the acquisition and disposal of company stock and derivative securities.

Summary

  • Jessica L. Mayer, Chief Legal/Compliance Officer of Cardinal Health, filed a Form 4 detailing changes in beneficial ownership of company stock.
  • On August 15, 2024, Mayer acquired 11,491 common shares through the grant of restricted stock units (RSUs) and exercised stock options to acquire 8,673 common shares.
  • Also on August 15, 2024, Mayer disposed of 18,807 shares to cover tax obligations related to vesting RSUs and performance share units, and sold 17,896 shares at an average price of $106.48.
  • On August 16, 2024, Mayer disposed of 1,985 shares to cover tax obligations related to vesting RSUs.
  • Following these transactions, Mayer directly owns 92,544 common shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there are stock sales, they are partially attributed to tax obligations, and the acquisition of shares through RSU grants is a positive sign.

Positives

  • The acquisition of shares through RSU grants and option exercises indicates Mayer's continued investment in Cardinal Health.
  • The vesting of RSUs signals a long-term incentive for Mayer to contribute to the company's success.

Negatives

  • The sale of shares could be interpreted as a lack of confidence, although it is partially attributed to covering tax obligations.

Risks

  • Executive stock sales can sometimes create negative market sentiment, although tax-related sales are common and often anticipated.
  • Fluctuations in Cardinal Health's stock price could impact the value of Mayer's holdings and future option exercises.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Comparison to Industry Standards

  • Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders.
  • The vesting schedules and exercise prices of these instruments are generally in line with industry norms.
  • Tax-related stock sales are a common occurrence among executives holding equity compensation.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders depending on how they interpret the stock sales.
  • Employees may view the RSU grants as a positive sign of the company's commitment to its executives.

Key Dates

DateDescription
08/15/2017First vesting date of employee stock option (right to buy) at $83.19.
08/15/2018Second vesting date of employee stock option (right to buy) at $83.19 and first vesting date of employee stock option (right to buy) at $66.43.
08/15/2019Third vesting date of employee stock option (right to buy) at $83.19 and second vesting date of employee stock option (right to buy) at $66.43.
08/15/2020Third vesting date of employee stock option (right to buy) at $66.43.
08/15/2024Date of stock transactions including RSU grants, option exercises, and share sales.
08/15/2025First vesting date of new RSU grants.
08/15/2026Expiration date of employee stock option (right to buy) at $83.19.
08/15/2027Expiration date of employee stock option (right to buy) at $66.43.
08/16/2024Date of stock transactions including share sales.
08/19/2024Date of Form 4 signature.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.